NASDAQ:ENGN enGene (ENGN) Stock Price, News & Analysis $8.89 +0.04 (+0.45%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About enGene Stock (NASDAQ:ENGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get enGene alerts:Sign Up Key Stats Today's Range$8.62▼$8.9550-Day Range$5.50▼$9.8352-Week Range$4.42▼$27.99Volume58,531 shsAverage Volume112,370 shsMarket Capitalization$393.08 millionP/E RatioN/ADividend YieldN/APrice Target$33.67Consensus RatingBuy Company OverviewenGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Read More… Why Buffett, Bezos, & Congress Are Piling Into This One Sector (Ad)Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…Click here for the details enGene Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks61st Percentile Overall ScoreENGN MarketRank™: enGene scored higher than 61% of companies evaluated by MarketBeat, and ranked 444th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingenGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageenGene has only been the subject of 2 research reports in the past 90 days.Read more about enGene's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for enGene are expected to decrease in the coming year, from ($1.56) to ($1.84) per share.Price to Book Value per Share RatioenGene has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.60% of the float of enGene has been sold short.Short Interest Ratio / Days to CoverenGene has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in enGene has recently increased by 63.09%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldenGene does not currently pay a dividend.Dividend GrowthenGene does not have a long track record of dividend growth.Read more about enGene's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.60% of the float of enGene has been sold short.Short Interest Ratio / Days to CoverenGene has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in enGene has recently increased by 63.09%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.21 News SentimentenGene has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for enGene this week, compared to 23 articles on an average week.Search Interest8 people have searched for ENGN on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat Follows10 people have added enGene to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, enGene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,651,103.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.70% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about enGene's insider trading history. Receive ENGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter. Email Address ENGN Stock News HeadlinesInsider Buying: enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Buys 2,750 Shares of StockOctober 19, 2024 | insidertrades.comInsider Buying: enGene Holdings Inc. (NASDAQ:ENGN) CEO Buys $57,000.00 in StockOctober 2, 2024 | insidertrades.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)OpenAI releases ChatGPT search engine, taking on GoogleNovember 2 at 2:43 AM | msn.comVerstappen handed 5-place grid penalty in Brazil after another engine changeNovember 2 at 2:43 AM | msn.comWhat Is ChatGPT Search? How to Use the AI Search EngineNovember 1 at 9:43 PM | msn.comOpenAI's new search engine sets off sparks of changeNovember 1 at 9:43 PM | msn.comChatGPT Is Now a Search EngineNovember 1 at 4:35 PM | msn.comSee More Headlines ENGN Stock Analysis - Frequently Asked Questions How have ENGN shares performed this year? enGene's stock was trading at $9.23 on January 1st, 2024. Since then, ENGN stock has decreased by 3.7% and is now trading at $8.89. View the best growth stocks for 2024 here. How were enGene's earnings last quarter? enGene Holdings Inc. (NASDAQ:ENGN) announced its quarterly earnings results on Tuesday, September, 10th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.05. How do I buy shares of enGene? Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of enGene own? Based on aggregate information from My MarketBeat watchlists, some other companies that enGene investors own include PayPal (PYPL), United Microelectronics (UMC), XPeng (XPEV), Adverum Biotechnologies (ADVM), AngioDynamics (ANGO), APi Group (APG) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings9/10/2024Today11/01/2024Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ENGN Previous SymbolNASDAQ:ENGN CUSIPN/A CIK1980845 Webwww.engene.com Phone302-273-0765FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$33.67 High Stock Price Target$40.00 Low Stock Price Target$30.00 Potential Upside/Downside+278.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-99,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-66.38% Return on Assets-56.00% Debt Debt-to-Equity Ratio0.09 Current Ratio19.52 Quick Ratio19.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$4.63 per share Price / Cash Flow1.92 Book Value$3.12 per share Price / Book2.85Miscellaneous Outstanding Shares44,220,000Free Float38,158,000Market Cap$393.12 million OptionableN/A Beta-0.69 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ENGN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.